2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 169

Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Abstract Number: 278

Is It Worth Allowing the Presence of Morning Stiffness in the Definition of Inactive Disease in Juvenile Idiopathic Arthritis?
Abstract Number: 1894

Is It Worth It to Include MRI of the Spine in the ASAS Classification Criteria for Axial Spondyloarthritis?
Abstract Number: 1632

Is Liopxin A4 a Biomarker for Systemic Lupus Erythematosus?
Abstract Number: 1239

Is Lymphocytic Sialadenitis IgG4-Related?
Abstract Number: 1229

Is NOD2-Associated Autoinflammatory Disease Remotely Related to Familial Mediterranean Fever or Continuum of It?
Abstract Number: 1339

Is Psychological Status Related to Symptom Experience in Behçet’s Syndrome?
Abstract Number: 2417

Is Remission Really Achievable in EARLY Rheumatoid Arthritis?
Abstract Number: 842

Is Rheumatoid Arthritis a Coronary Heart Disease Risk Equivalent, Similar to Diabetes?
Abstract Number: 2812

Is Rheumatoid Arthritis the Same Disease in Women and Men?- Joint Damage in Patients with EARLY Rheumatoid Arthritis at 10 YEARS after Diagnosis
Abstract Number: 202

Is Schuss View Alone Enough for the Diagnosis of Femorotibial Osteoarthritis ? the Khoala Cohort Study
Abstract Number: 116

Is Socioeconomic Status at Diagnosis Associated with Long-Term Direct Medical Costs in Systemic Sclerosis? a General Population-Based Cohort Study
Abstract Number: 2073

Is Susceptibility to Fibromyalgia a Trait?
Abstract Number: 1809

Is Team Care Better? a Comparison of Rheumatoid Arthritis Disease Activity Among Patients Cared for in Practices with Nurse Practitioners and Physicians Assistants Versus Rheumatologist Only
Abstract Number: 792

Is Temporal Artery Biopsy the Gold Standard for the Diagnosis of Giant Cell Arteritis?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].